Gait Parameters Alterations Under Dual-Task Conditions in Patients With Acquired and Hereditary Peripheral Neuropathies.

Multiple Sclerosis in Charcot-Marie-Tooth Disease Type 1A - A Case Report and Literature Review.

Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes.

Hypertrophy of great auricular nerve in Charcot-Marie-Tooth disease type 1A.

Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies.

Characterising PMP22-Proximal Partners in a Schwann Cell Model of Charcot-Marie-Tooth Disease Type1A.

Search for Additional Pathogenic Variants to Explain Variation in PMP22-Related Neuropathies.

A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.

Guillain-Barré Syndrome With Asymmetrical Weakness in a Patient With Charcot-Marie-Tooth Disease Type 1A.

The Easy Handgrip Test as a Tool for Assessing Motor Fatigability in Children With Charcot-Marie-Tooth Disease Type 1A.

Concurrent FHL1-Related Myopathy and CMT1A Unveiled by Persistent Neuropathic Feature.

Effectiveness of Sitagliptin and Empagliflozin Combination Therapy in a Patient With Charcot-Marie-Tooth Disease and Comorbid Diabetes Mellitus: A Case Report.

[Precise preimplantation genetic testing for a Chinese pedigree carrying a small segmental copy number variation].

Untargeted lipidomic deep-profiling of human plasma via high-performance aza-Prilezhaev aziridination-LC-MS: Unraveling CC isomeric signatures of Charcot-Marie-Tooth disease.

Clinical and genetic characteristics associated with dual-positive gene variations.

Establishment of an In Vitro Disease Model of Charcot-Marie-Tooth Disease using Human Induced Pluripotent Stem Cells.

Nerve Diameter and DTI Parameters Maybe Potential Markers for Clinical Trial in Patients With Charcot-Marie-Tooth Disease Type 1A.

Dynamic regulation of Rgs16 and its correlation with Neuregulin1 expression in acute and chronic nerve injury.

Nonrecurrent 17p duplications in two patients with developmental and neurological abnormalities.

Guillain-Barré syndrome in patients with Charcot-Marie-Tooth type 1A disease, probably a non-random association.

A case report of a MODY6 patient coexistence with Charcot-Marie-Toothe 1A syndrome.

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Neurogenic disease with high CK: think muscle.

Synergistic effect of Wharton's jelly-derived mesenchymal stem cells and insulin on Schwann cell proliferation in Charcot-Marie-Tooth disease type 1A treatment.

The recovery cycle of excitability assessed by a conventional electrodiagnostic machine: A study in healthy volunteers and in Charcot-Marie-Tooth 1A patients.

Unveiling a Rare Coexistence: Duchenne Muscular Dystrophy with Charcot-Marie-Tooth Disease Type 1A Presentation.

p62/sequestosome-1 as a severity-reflecting plasma biomarker in Charcot-Marie-Tooth disease type 1A.

PMP22 duplication dysregulates lipid homeostasis and plasma membrane organization in developing human Schwann cells.

Quantitative Foot Muscle Magnetic Resonance Imaging Reliably Measures Disease Progression in Children and Adolescents with Charcot-Marie-Tooth Disease Type 1A.

A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot-Marie-Tooth neuropathy 1A.

[Genetic analysis of a Chinese pedigree affected with atypical Charcot-Marie-Tooth disease type 1A due to duplication of PMP22 gene].

Improvement of Charcot-Marie-Tooth Phenotype with a Nanocomplex Treatment in Two Transgenic Models of CMT1A.

Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication.

Testing SIPA1L2 as a modifier of CMT1A using mouse models.

Intermediate conduction velocity in two cases of Charcot-Marie-Tooth disease type 1A.

Targeting PI3K/Akt/mTOR signaling in rodent models of PMP22 gene-dosage diseases.

Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.

Home-based multi-sensory and proximal strengthening program to improve balance in Charcot-Marie-Tooth disease Type 1A: A proof of concept study.

Preclinical Efficacy of Peripheral Nerve Regeneration by Schwann Cell-like Cells Differentiated from Human Tonsil-Derived Mesenchymal Stem Cells in C22 Mice.

AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells.

Gait Pattern in Charcot-Marie-Tooth Disease Type 1A According to Disease Severity.

Evaluation of the median nerve by shear wave elastography in patients with Charcot-Marie-Tooth disease type 1A.

Post-transcriptional microRNA repression of PMP22 dose in severe Charcot-Marie-Tooth disease type 1.

Disease-specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot-Marie-Tooth disease type 1A.

TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A.

Mechanisms and treatment strategies of demyelinating and dysmyelinating Charcot-Marie-Tooth disease.

The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22.

Young infants with PMP22 duplication can have minor nerve conduction study abnormalities.

Magnetic resonance imaging-based lower limb muscle evaluation in Charcot-Marie-Tooth disease type 1A patients and its correlation with clinical data.

Evidence of nerve hypertrophy in patients with inclusion body myositis on lower limb MRI.

Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study.

Peripheral Myelin Protein 22 Gene Mutations in Charcot-Marie-Tooth Disease Type 1E Patients.

A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.

Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice.

Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies.

Nerve Ultrasound Findings before and after Surgery in a Patient with Charcot-Marie-Tooth Disease Type 1A and Comorbid Carpal Tunnel Syndrome.

Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.

SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot-Marie-Tooth disease Type 1A mouse model.

Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.

Intraepineurial fat quantification and cross-sectional area analysis of the sciatic nerve using MRI in Charcot-Marie-Tooth disease type 1A patients.

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.

Cardiopulmonary exercise performance and factors associated with aerobic capacity in neuromuscular diseases.

Quantitative assessment of muscle echogenicity in Charcot-Marie-Tooth disease type 1A by automatic thresholding methods.

Prevalence and characterization of pain in patients with Charcot-Marie-Tooth disease type 1A.

MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A.

High-density surface electromyography to assess motor unit firing rate in Charcot-Marie-Tooth disease type 1A patients.

A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.

Aquaporin-4-antibody-positive Neuromyelitis Optica Spectrum Disorder in a Patient with Charcot-Marie-Tooth Disease Type 1A.

Short hairpin RNA treatment improves gait in a mouse model of Charcot‑Marie‑Tooth disease type 1A.

Central nervous system impairment detected by somatosensory evoked potentials in patients with Charcot-Marie-Tooth disease type 1A.

Charcot-Marie-Tooth disease type 1A: Longitudinal change in nerve ultrasound parameters.

Diffuse brain connectivity changes in Charcot-Marie-Tooth type 1a patients: a resting-state functional magnetic resonance imaging study.

Intraepidermal nerve fibre density as biomarker in Charcot-Marie-Tooth disease type 1A.

Rate of Changes in CMT Neuropathy and Examination Scores in Japanese Adult CMT1A Patients.

Paternal gender specificity and mild phenotypes in Charcot-Marie-Tooth type 1A patients with de novo 17p12 rearrangements.

Vagus Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Charcot-Marie-Tooth Disease Type 1A.

Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.

Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners.

Subcellular diversion of cholesterol by gain- and loss-of-function mutations in PMP22.

Pmp22 super-enhancer deletion causes tomacula formation and conduction block in peripheral nerves.

High glucose level as a modifier factor in CMT1A patients.

[Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A].

Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A.

Multidimensional evaluation is necessary to assess hand function in patients with Charcot-Marie-Tooth disease type 1A.

A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.

Neuropathic pain in patients with Charcot-Marie-Tooth type 1A.

Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.

Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy.

Foot Function Index: A Promising Questionnaire for Individuals With Charcot-Marie-Tooth Disease Type 1A.

miR-381 Attenuates Peripheral Neuropathic Phenotype Caused by Overexpression of PMP22.

Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study.

Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity.

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies.

Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A.

Replication studies of MIR149 association in Charcot-Marie-Tooth disease type 1A in a European population.

Replication studies of MIR149 association in Charcot-Marie-Tooth disease type 1A in a European population - response.

Reversible conduction failure on the deep tendon reflex response recording in early Guillain-Barré syndrome.

Fontan Failure Secondary to Charcot-Marie-Tooth-Induced Phrenic Neuropathy.

Walking Speed Is Correlated With the Isokinetic Muscular Strength of the Knee in Patients With Charcot-Marie-Tooth Type 1A.

Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A.

Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells into Schwann-Like Cells Improves Neuromuscular Function in a Mouse Model of Charcot-Marie-Tooth Disease Type 1A.

Hidden hearing loss in patients with Charcot-Marie-Tooth disease type 1A.

Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A.

Dejerine-Sottas disease in childhood-Genetic and sonographic heterogeneity.

Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.

Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs.

Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A.

Established and novel measures of upper limb impairment in children with Charcot-Marie-tooth disease type 1A and riboflavin transporter deficiency type 2.

Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.

Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.

Caveats in the Established Understanding of CMT1A.

Application of differentiated human tonsil-derived stem cells to trembler-J mice.

Unusual de novo Partial Trisomy 17p12p11.2 due to Unbalanced Insertion into 5p13.1 in a Severely Affected Boy.

Hand involvement in Charcot-Marie-Tooth disease type 1A may resemble rheumatoid arthritis.

A case report of hereditary neuropathy with liability to pressure palsies accompanied by type 2 diabetes mellitus and psoriasis.

Charcot-Marie-Tooth disease type 1C: Clinical and electrophysiological findings for the c.334G>a (p.Gly112Ser) Litaf/Simple mutation.

A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.

Handwriting difficulties of children with Charcot-Marie-Tooth disease type 1A.

Abl2 kinase phosphorylates Bi-organellar regulator MNRR1 in mitochondria, stimulating respiration.

A New Next-Generation Sequencing-Based Assay for Concurrent Preimplantation Genetic Diagnosis of Charcot-Marie-Tooth Disease Type 1A and Aneuploidy Screening.

Coexistent Charcot-Marie-Tooth type 1A and type 2 diabetes mellitus neuropathies in a Chinese family.

Nonrecurrent 17p11.2p12 Rearrangement Events that Result in Two Concomitant Genomic Disorders: The PMP22-RAI1 Contiguous Gene Duplication Syndrome.

[Ascorbic Acid and Charcot-Marie-Tooth Disease].

Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.

Spinal and bulbar muscular atrophy and Charcot-Marie-Tooth type 1A: Co-existence of two rare neuromuscular genetic diseases in the same patient.

Respiratory dysfunction in Charcot-Marie-Tooth disease type 1A.

Inducible HSP70 is critical in preventing the aggregation and enhancing the processing of PMP22.

Peripheral nerve ultrasound in pediatric Charcot-Marie-Tooth disease type 1A.